Home' Australian Pharmacist : Australian Pharmacist October 2012 Contents 822 Australian Pharmacist October 2012 I © Pharmaceutical Society of Australia Ltd.
Submit your answers online before
1 December 2012 at www.psa.org.
au and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4
out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
If not submitting online, write the correct answers
in the spaces provided on the answer panel on
the back of the address sheet, fill in your name,
member number and address details, then either
mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. Which of the following statements is
a) PMR is a common inflammatory
condition of elderly people
characterised by proximal pain and
morning stiffness which last for up to
b) The relationship between PMR and
GCA is not clearly established.
c) Incidence of PMR and GCA increases
after the age of 50 and peaks between
70–80 years of age.
d) When symptoms of PMR do not
respond to corticosteroids, NSAIDs use
will alleviate symptoms of morning
2. Which of the following is NOT
regularly recommended for the
prevention of corticosteroid
a) Participation in weight bearing
b) Supplementing diet with calcium
(1000 to 1500 mg/day).
c) Supplementing diet with vitamin D
d) The use of calcitonin.
3. Which of the following statements
regarding OA is MOST accurate?
a) OA presents as joint pain and 25% of
people with OA over the age of 55
years have a persistent episode of knee
b) Although OA is common in the knee,
it is even more prevalent in the
hand, and when symptomatic this is
associated with functional impairment.
c) The joint pain of OA is described as
being exacerbated by activity and
relieved by rest.
d) All of the above are equally accurate.
4. Which of the following
non conventional regimens is NOT
RECOMMENDED for OA?
d) Spa therapy.
1. eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines;
Rheumatology; Vasculitis syndromes; polymyalgia rheumatic
and giant cell arteritis; clinical presentation.
2. American college of rheumatology. Practice management.
Polymyalgia Rheumatica. At: www.rheumatology.org/
3. Falardeau J. Giant Cell Arteritis. Neurologic Clinics. Aug
4. Salvarani C. Cantini F. Boiardi L, Hunder G. Polymyalgia
rheumatica and giant-cell arteritis. The New England Journal of
Medicine. At: www.nejm.org/doi/full/10.1056/NEJMra011913
5. Hutchings A, Hollywood J, Lamping DL, et al. Clinical
outcomes, quality of life, and diagnostic uncertainty in the
first year of polymyalgia rheumatica. Arthritis & Rheumatism,
2007;57:803–09 . Doi: 10.1002/art.22777
6. Papadopoulos P. Polymyalgia Rheumatica. Medscape refrence
drugs, disease and procedures found at: http://emedicine.
7. Polymyalgia Rheumatica (PMR) & Giant Cell Arteries ( Temporal
Arteritis) found at: www.medicinenet.com/polymyalgia_
8. Kennedy S. (), Polymyalgia rheumatica and giant cell arteritis:
An in-depth look at diagnosis and treatment. Journal of the
American Academy of Nurse practitioners, 2012;24:277–85.
9. Fessier B. Polymyalgia Rheumatica and Giant Cell arteritis. Bope
and Kellerman: Conn’s Current therapy 2012, 1st edition (2011).
10. Hellmann D. Giant Cell arteritis, polymyalgia rheumatica and
Takayasu’s Arteritis. Kelly’s textbook of rheumatology, 8th
11. PubMed Health. Polymyalgia rheumatica. At: www.ncbi.nlm.
12. The Royal Australian College of General Practitioners.
Guidelines for the non-surgical management for hip and knee
osteoarthritis. Jul 2009. At: www.racgp.org.au/guidelines/
13. Lozada C. Management of osteoarthritis. Kelly ’s textbook of
rheumatology, 8th edition. 2008.
14. NPS news 18: Osteoarthritis- have COX-2 changed its
management. At: www.nps.org.au/health_professionals/
15. Towheed TE, Judd MJ, Hochberg MC, Well G. Acetaminophen
for osteoarthritis. Cochrane Database system 2003.At: www.
Links Archive Australian Pharmacist September 2012 Australian Pharmacist November 2012 Navigation Previous Page Next Page